Calcitriol supplementation accelerates the recovery of patients with tuberculosis who have vitamin D deficiency: a randomized, single-blind, controlled clinical trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

This study aimed to evaluate whether calcitriol supplementation enhances CD4+ T cell count and prognosis in patients with tuberculosis and low 25(OH)D levels.

Who Took Part

This randomized controlled clinical trial enrolled treatment-naïve patients with tuberculosis admitted to Zigong First People's Hospital (June 2016 to April 2017).

All patients were treated with the 2HRZE/4HR regimen.

How the Study Was Run

The design is described as randomized, double-blind and single-blind.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Only one side, usually the participants, was kept unaware of whether Vitamin D, K2, Magnesium and Zinc was given.

The Low-Vit-D group was randomized to the Low-25(OH)D and Low-25(OH)D-Calcitriol groups.

What Was Measured

PubMed files the paper under topics including Calcitriol, Cholecalciferol, Dietary Supplements, Tuberculosis, Vitamin D and Vitamin D Deficiency.

Author keywords: 25-(OH) D and CD4+ T cells.

What This Means in Plain Language

The paper is a randomized, double-blind and single-blind study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2022 (BMC infectious diseases), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.